Avis Budget Group, Inc. (CAR)
Kyverna Therapeutics: The Autoimmune CAR T Beachhead Is Bigger Than SPS
Kyverna Therapeutics is positioned to pioneer the autoimmune CAR T space, leveraging miv-cel as a potential first-in-class therapy for severe B-cell-driven autoimmune diseases. Recent regulatory alignment enables a rolling BLA submission for SPS, with pivotal single-arm Phase 2 data showing strong efficacy and safety, targeting FDA approval by late 2026. KYTX maintains a cash runway through 2028, supported by $236M in cash and a $150M credit facility, enabling completion of key trials and commercial launch preparation.
Allogene Therapeutics: A High-Upside Bet On The Next Wave Of CAR-T Innovation
Allogene Therapeutics offers upside potential driven by the pivotal ALPHA3 trial for Cema-cel in first-line large B-cell lymphoma, with a key readout in mid-2027. ALLO-329's early clinical signals in autoimmune disease, leveraging proprietary Dagger technology, set up a differentiated, scalable CAR-T platform with high-value optionality. ALLO demonstrates improving financial discipline, reducing quarterly net loss to $42.6M and extending cash runway into early 2029 following a $200.4M public offering.
Strong Car Rental Demand Aids Avis Budget Group Amid Low Liquidity
CAR gains from rising demand for short-term vehicle rentals, but geopolitical risks, low liquidity and lack of dividend cloud its long-term outlook.
Avis Wins $650 Million From Hedge Fund That Bet Big on Its Stock
Pentwater Capital agrees to pay Avis Budget after it was accused of fueling excess volatility in the car-rental company's stock.
Reasons Why You Should Retain Avis Budget Stock in Your Portfolio
CAR shares jump 28% in a month as pricing improves, fleet utilization hits a 15-year high and earnings are projected to surge in 2026.
Lyell Immunopharma: Undervalued Ahead Of A Major CAR-T Inflection
Lyell Immunopharma (LYLE) offers asymmetric upside, with ronde-cel showing best-in-class durability and safety in relapsed/refractory LBCL. LYLE trades near cash value, with the market heavily discounting its pipeline despite advanced pivotal trials and strong early efficacy signals. Ronde-cel's dual CD19/CD20 targeting and CD62L+ enrichment underpin durable responses, low severe toxicity, and potential for outpatient administration.
Caribou Biosciences Says CRISPR CAR-T Is Pivotal-Ready, CB-011 Data Nears
Caribou Biosciences NASDAQ: CRBU Chief Executive Officer Rachel Haurwitz said the company is advancing two CRISPR-enabled, off-the-shelf CAR T cell therapy programs, with its lymphoma candidate vispa-cel now “pivotal-ready” and its multiple myeloma program CB-011 continuing in Phase 1 development.
Why Is Avis Budget (CAR) Down 3.2% Since Last Earnings Report?
Avis Budget (CAR) reported earnings 30 days ago. What's next for the stock?
CAR's Strategic Mobility Partnerships Offer Long-Term Opportunities
Avis Budget is expanding mobility partnerships and premium services as it positions itself beyond traditional car rentals.
Lyell Immunopharma Targets 2027 FDA Filing as CAR-T Pipeline Advances
Lyell Immunopharma NASDAQ: LYEL President and CEO Lynn Seely outlined the company's clinical development priorities, regulatory strategy and manufacturing plans during a Stifel investor session moderated by Stephen Willey, senior biotech analyst at Stifel.
Avis Budget's Pricing Recovery Signals Improving Industry Discipline
CAR's pricing rebound and tighter fleet management are boosting utilization and improving depreciation trends.
CAR's Recovery Remains Weak After Extreme Volatility: Hold or Fold?
CAR's pricing recovery and Waymo partnership offer long-term potential, but April's 70% stock collapse exposed major volatility risks.
